Topics

Manufacturing 'Grand Challenge' targets pharma to develop continuous formulation platform

05:05 EDT 10 Oct 2019 | EPM Magazine

A new initiative will see the Centre for Process Innovation (CPI) work with the University of Strathclyde, GSK and AstraZeneca to develop a platform to accelerate the development of oral solid dosage formulations.

Related Biotechnology, Pharmaceutical and Healthcare News

Original Article: Manufacturing 'Grand Challenge' targets pharma to develop continuous formulation platform

NEXT ARTICLE

More From BioPortfolio on "Manufacturing 'Grand Challenge' targets pharma to develop continuous formulation platform"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...


News Quicklinks

Search Biotech, Medical and Healthcare News

Popular Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches

BioPortfolio Limited Social Media
Publish Content Agreements
Tools Help

HON Code certificate This site complies with the HONcode standard for trustworthy health information:
Verify here.

The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored ND2A Group with offices at 677 Craig Rd, Suite 216, Creve Coeur, Missouri 63141 USA. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters here: Contact ND2A Group.

All rights reserved. All other trademarks recognized. Copyright © 2019 ND2A Group. Site developed by Alacrify Ltd

.